MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’
After BioNTech, German VC Leader Looks To Next Challenge
MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.
You may also be interested in...
Gaming Industry Entrepreneur Backs Ethris To Be Germany’s Next mRNA Pioneer
An online gaming entrepreneur is injecting new cash and strategic thinking into biotech Ethris – with the goal of making it a ‘gamechanger’ in inhaleable mRNA.
Investors Back iOmx’s Focus On Tumor Immune Evasion
The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022
AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio
Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.